Hyloris announces US FDA approval of Maxigesic® IV
Maxigesic IV, a strong non-opioid analgesic, is marketed in the US under the trade name Combogesic IV First US sales expected early 2024, generating $2.1 million milestone payout Lige, Belgium October 18, 2023 7am CET Regulated Information – Internal Information – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharmaceutical company committed to addressing unmet … Read more